Publication, Part of [MI] Cancer Quality of Life Survey
[MI] Cancer Quality of Life Survey, Invites up to December 2022
Survey
Summary
The Cancer Quality of Life Survey is an ongoing national survey run by the NHS in England. The survey is for people in England who have had a cancer diagnosis, with people invited to complete the survey around 18 months after diagnosis. It has been running since September 2020, with a gradual roll-out to all cancer types.
The aim of the survey is to find out how quality of life may have changed for people diagnosed with cancer. The survey asks people who have experienced cancer how they are feeling. Their answers will be compared with information about their cancer diagnosis and treatment. This will help the NHS see where care is working well or not so well, and if any new services are needed. It will help the NHS to improve the way it supports people to live as long and as well as possible. The survey is made up of two questionnaires which measure overall health (EQ-5D) and quality of life (EORTC QLQ-C30).
The survey results are reported in an interactive dashboard, including summary score measures and more detailed measures of different aspects of quality of life, including aspects of health (such as mobility), functional categories (such as emotional) and symptoms (such as fatigue). Results are reported by geographies and cancer types, and with breakdowns by demographic groups.
This release updates the data included in the dashboard, to additionally include data for patients invited up to December 2022, and to include response data received up to 7 February 2023. For the first time, the dashboard provides data adjusted for age, gender, and cancer type (where relevant), alongside unadjusted data, to enable more accurate comparisons between selections of cancer type and geography. This release provides data for a number of additional broad and detailed cancer types. The dashboard has been restructured for this release to make the user experience more intuitive.
Key Facts
47% of people with cancer who received a survey invite responded
equating to 111,470 responses from the 239,629 people invited
Cancer patients on average scored 74 out of 100, compared to 90 in the general population (adjusted for age and gender)
for an overall health summary score, where higher scores suggest better quality of life
Comparing broad cancer types, melanoma patients had the highest average summary scores, suggesting better quality of life, with lung cancer patients having the lowest average summary scores
based on four summary measures of quality of life (adjusted for age and gender)
Background
The data is presented by combinations of selected:
- Geographies: England, NHS regions, Cancer Alliances, Integrated Care Boards and Trusts at diagnosis.
- Cancer sites:
- Broad groups: Bone and soft-tissue, Brain and CNS, Breast, Colorectal, Endocrine, Gynaecological, Haematological, Head and neck, Lung, Melanoma, Prostate, Upper gastrointestinal, Urological, Other.
- Detailed groups: Colon, Rectal, Cervical, Ovarian, Uterine, Other gynaecological, Leukaemia, Multiple myeloma, Non-Hodgkin lymphoma, Other haematological, Oesophageal, Pancreatic, Stomach, Liver and other upper gastrointestinal, Bladder, Kidney and urinary tract, Testicular.
- Demographic groups: gender, age at diagnosis, ethnic group, deprivation area and stage at diagnosis.
Feedback
Feedback can be sent to: [email protected]. This email address can be used for general enquiries to NDRS. Please do not include sensitive or patient identifiable information.
Last edited: 7 March 2024 2:55 pm